Trial · NCT01332331
Results by group176
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 176
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Treatment-emergent Adverse Events (SAEs) | Low Dose Ambrisentan | Any AEs | 16 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Treatment-emergent Adverse Events (SAEs) | High Dose Ambrisentan | Any AEs | 16 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Treatment-emergent Adverse Events (SAEs) | Low Dose Ambrisentan | Any SAEs | 6 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Treatment-emergent Adverse Events (SAEs) | High Dose Ambrisentan | Any SAEs | 2 | Participants | |
Number of Participants With Post Baseline Potential Clinical Importance (PCI) Value for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin and Creatinine | Low Dose Ambrisentan | ALT | 0 | Participants | |
Number of Participants With Post Baseline Potential Clinical Importance (PCI) Value for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin and Creatinine | High Dose Ambrisentan | ALT | 0 | Participants | |
Number of Participants With Post Baseline Potential Clinical Importance (PCI) Value for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin and Creatinine | Low Dose Ambrisentan | AST | 0 | Participants | |
Number of Participants With Post Baseline Potential Clinical Importance (PCI) Value for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin and Creatinine | High Dose Ambrisentan | AST | 0 | Participants | |
Number of Participants With Post Baseline Potential Clinical Importance (PCI) Value for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin and Creatinine | Low Dose Ambrisentan | GGT | 0 | Participants | |
Number of Participants With Post Baseline Potential Clinical Importance (PCI) Value for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin and Creatinine | High Dose Ambrisentan | GGT | 0 | Participants | |
Number of Participants With Post Baseline Potential Clinical Importance (PCI) Value for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin and Creatinine | Low Dose Ambrisentan | Total bilirubin | 1 | Participants | |
Number of Participants With Post Baseline Potential Clinical Importance (PCI) Value for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin and Creatinine | High Dose Ambrisentan | Total bilirubin | 0 | Participants | |
Number of Participants With Post Baseline Potential Clinical Importance (PCI) Value for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin and Creatinine | Low Dose Ambrisentan | Creatinine | 0 | Participants | |
Number of Participants With Post Baseline Potential Clinical Importance (PCI) Value for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin and Creatinine | High Dose Ambrisentan | Creatinine | 0 | Participants | |
| Number of Participants With Post Baseline PCI Value for Hematology Parameter: Hemoglobin | Low Dose Ambrisentan | Reference high range | 0 | Participants | |
| Number of Participants With Post Baseline PCI Value for Hematology Parameter: Hemoglobin | High Dose Ambrisentan | Reference high range | 2 | Participants | |
| Number of Participants With Post Baseline PCI Value for Hematology Parameter: Hemoglobin | Low Dose Ambrisentan | Reference low range | 1 | Participants | |
| Number of Participants With Post Baseline PCI Value for Hematology Parameter: Hemoglobin | High Dose Ambrisentan | Reference low range | 0 | Participants | |
| Number of Participants With Post Baseline PCI Value for Hematology Parameter: Hematocrit | Low Dose Ambrisentan | Reference high range | 0 | Participants | |
| Number of Participants With Post Baseline PCI Value for Hematology Parameter: Hematocrit | High Dose Ambrisentan | Reference high range | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01332331/results